Chief Technology Officer and co-founder of TissueTech, Scheffer C. G. Tseng, MD, PhD has received grant support from the National Institutes of Health and the National Eye Institute since 1985. Basic and clinical research conducted under his oversight is related to the improvement of the diagnosis and treatment of ocular surface diseases. Examples of his translational research include coining the term and establishment of the diagnosis of limbal stem cell deficiency, pioneering autologous and allogeneic limbal stem cell transplantation, and amniotic membrane transplantation to restore sight in patients with corneal blindness caused by limbal stem cell deficiency.
From 2002 to 2014, scientists at TissueTech focused on searching for the molecular mechanism of amniotic membrane and umbilical cord human birth tissue to deliver anti-inflammatory and anti-scarring actions to promote wound healing. This included the identification and characterization of heavy chain-hyaluronic acid-pentraxin 3 (HC-HA/PTX3) as a unique extracellular matrix responsible for the amniotic membrane’s therapeutic actions. Today, TissueTech, Inc. and its subsidiaries Amniox Medical and BioTissue, Inc. are pursuing rigorous Investigational New Drug clinical trials to support a Biologics Licensing Application. All TissueTech commercial products are regulated as either 361 Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) or 510(k) devices.
With more than 30 years of experience, Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer, Board Member and Co-Founder of TissueTech, Inc. is available to speak on scientific research. His research focus for the past 30 years has been to identify the active biological components of human placental tissues, to develop alternative products to deliver their therapeutic properties, and to expand their clinical applications.
Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer and Co-Founder, Board Member, TissueTech, Inc.
- Board Certification by American Board of Ophthalmology
- Bachelor of Science, National Taiwan University, Taiwan
- Medical Degree, Medical School, National Taiwan University, Taiwan
- Doctorate in Experimental Pathology, University of California, San Francisco, CA
- Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Florida; Professor (Tenured), Charlotte Breyer Rodgers Chair in Ophthalmology; 1998-2001
- Inaugural President, International Ocular Surface Society, 2001-2004
- American Academy of Ophthalmology Senior Achievement Award 2004, Secretariat Award 2005, and Life Achievement Honor Award 2016
- 2017 ARVO Gold Fellow, Association for Research in Vision and Ophthalmology, Inc.
Dr. Tseng is the co-founder of TissueTech and a world-renowned surgeon in ocular surface reconstruction. His research has been continuously supported by the National Institutes of Health National Eye Institute for more than 34 years; he is a widely published physician scientist with more than 360 peer-reviewed clinical and scientific papers. Dr. Tseng pioneered limbal stem cell transplantation and developed and commercialized the CryoTek process to preserve the natural therapeutic properties of amniotic membrane. His research focus for the past 30 years has been to identify the active biological components of human placental tissues, to develop alternative products to deliver their therapeutic properties, and to expand their clinical applications.